Publications by authors named "J R Westin"
Purpose: Extranodal NK/T-cell lymphoma (ENKTCL) is rare in the Western Hemisphere and is commonly treated with combined modality therapy (CMT).
Methods And Materials: We retrospectively reviewed 35 patients treated with Ann Arbor stage I/II ENKTCL between 1994 and 2015 at a large academic cancer center in the United States.
Results: With 11.
Antibiotic-induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpoint inhibitors and chimeric antigen receptor T (CAR-T) cell therapies. In this study, we observed that prior exposure to broad-spectrum ABX with extended anaerobic coverage like piperacillin-tazobactam and meropenem was associated with worsened anti-CD19 CAR-T therapy survival outcomes in large B-cell lymphoma patients (n=422), compared to other ABX classes. In a discovery subset of these patients (n=67), we found that the use of these ABX was in turn associated with substantial dysbiosis of gut microbiome function, resulting in significant alterations of the gut and blood metabolome, including microbial effectors such as short-chain fatty acids (SCFAs) and other anionic metabolites, findings that were largely reproduced in an external validation cohort (n=58).
View Article and Find Full Text PDFArticle Synopsis
- The development of anti-CD19 CAR T-cell therapies and bispecific antibodies is changing how diffuse large B-cell lymphoma (DLBCL) is treated, particularly for patients who struggle with traditional therapies.
- Researchers are exploring new immunotherapeutic strategies, including those that use both the adaptive and innate immune systems, to provide more treatment options for DLBCL patients.
- Combining various immunotherapies, and integrating them with oncogenic pathway inhibitors, could improve effectiveness by overcoming resistance and reprogramming the tumor environment.
Article Synopsis
- Researchers looked at how bridging radiation therapy (bRT) affects people getting CAR T-cell therapy for a type of cancer called large B-cell lymphoma.
- They found that bRT can be safely given, but it didn't seem to help or hurt the patients' outcomes in terms of blood cell counts or how well they responded to the CAR T-cell treatment.
- The study suggests that while bRT is safe, careful planning is needed to manage any risks after the treatment.